Skip to content

Trial pill-taking patterns were associated with progression to psychosis

An exploratory analysis linked lower adherence to study capsules with later psychosis, regardless of whether participants received fish oil or placebo.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Participants who took less of their assigned study medication were more likely to progress to psychosis. The association remained after adjustment for several measured factors and was independent of treatment assignment. Because adherence itself was not randomly assigned, these findings cannot show that taking the capsules prevented psychosis or that fish oil was effective.

Keep in mind

This abstract-based analysis cannot establish why adherence and psychosis were related. The psychosis assessment timeframe is unspecified, and statistical adjustment does not turn the adherence comparison into a causal test.

THE RESULT, WITH CONTEXT

What researchers found

Higher risk with non-adherence

Progression to psychosis

Non-adherent versus adherent participants; the association persisted in adjusted analysis. Adherence covered 6 months, but the psychosis follow-up interval was not reported.

Aust N Z J Psychiatry, 2025 · Original source ↓

What adherence meant

Researchers classified participants by how consistently they took the assigned capsules. They also checked a definition based on returned pills. Both approaches linked non-adherence with progression, suggesting the observation was not limited to a single definition.

A possible marker

Non-adherence was also associated with smoking, cannabis use, functioning, and symptom history. These connections make pill-taking behavior potentially informative about risk, but the abstract does not establish the pathway connecting that behavior with psychosis.

CHECK THE ORIGINAL

The original publication

Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study.

Schlögelhofer M, Lin A, Markulev C et al.
Aust N Z J Psychiatry · 2025

PubMed ID
40855720
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.